3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Temozolomide
8
Irinotecan
7
Melphalan
6
Cyclophosphamide
6
X-Rays
5
Topotecan
5
Phantoms, Imaging
5
Magnetic Resonance Spectroscopy
5
Granulocyte Colony-Stimulating Factor
5
Specimen Handling
4
Nuclear Medicine Department, Hospital
4
Busulfan
4
palbociclib
3
fludarabine
3
Vincristine
3
Thiotepa
3
Stem Cell Transplantation
3
Sirolimus
3
Nivolumab
3
Etoposide
3
Bone Marrow Transplantation
3
Biopsy
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
tazemetostat
2
selpercatinib
2
omburtamab I-131
2
olaparib
2
larotrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
pegylated granulocyte colony-stimulating factor
×
CNS
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled